IADR Innovation in Oral Care Awards
Supported by an unrestricted grant from GlaxoSmithKline
Deadline: December 12, 2014!
Online submission site opening soon!
The Innovation in Oral Care Awards (“Award(s)”) are jointly sponsored by IADR and GlaxoSmithKline (GSK), with funding provided exclusively by GSK. The IADR mission is to advance research and increase knowledge for the improvement of oral health worldwide. It does so through its Divisions and Sections as well as in partnership with international dental associations, industry, health agencies, and scientific and educational professional organizations. These innovation awards offer opportunities for investigators to conduct dental research that will have a direct impact on the oral health of the public.
As a leader in consumer oral care, GSK recognizes the need for pioneers to produce innovative technologies that can be used routinely by the public to maintain and improve oral health and quality of life. The Award(s) is intended to help investigators pursue innovative and novel research in oral care, above and beyond the bounds of traditional dental research.
Competitive Award(s), of up to $75,000 each, will be provided to recipients to advance oral care programs directed toward the development of innovative and novel compounds, biomaterials or devices that can be used ultimately at the public health level. Examples of areas of interest could include, but not be limited to:
- inhibition or removal of biofilms etc. adhering to natural or artificial surfaces,
- modification of those surfaces to inhibit biofilms and other deposits, stains and odors,
- adhesives for removable prosthetic devices,
- inhibition of tooth surface loss and gingival recession, and amelioration of their effects, and
- counteracting the oral effects of dry mouth, systemic illness, hormonal disturbances or physiological aging.
The Award(s) will be provided in the form of an unrestricted research grant which carries no obligation to the recipient’s organization for licensure, patenting, or transfer confidential information, although GSK may discuss the possibility of future collaboration with some applicants.
For the purposes of this Award Program, oral care is defined as:
- products, devices or delivery systems used frequently by consumers to maintain or improve their oral health status and quality of life, and/or
- devices fabricated by the assistance of dental professionals and placed in the oral cavity, and which require frequent or daily maintenance by the consumer.
- Any proposed innovation or new technology should provide significant benefits to the consumer, such as improved oral health and/or quality of life.
- Ultimately the proposed innovations or technologies should be available to large numbers of people through retail channels such as ‘over-the-counter’ (OTC) or general sale. Initially, however, it may be appropriate for availability to be on a prescription basis for a limited period before transitioning to OTC.
- Restorative materials, dental instruments and equipment, and diagnostics for non-oral conditions should not receive much consideration unless the technological advance provides significant benefit to the oral health and quality of life status of the public.
- The principal investigator listed in the application must be a current member of, or at the time of submission have made bona fide application to, IADR.
- To fulfill the quest for innovation, proposals should be collaboratively sponsored by at least one researcher whose principal expertise is in an area of biotechnology other than a dental science.
- The intent is to encourage collaboration with researchers from outside the dental institution; nevertheless, the most important criterion involves the innovative nature of the proposed research.
- Applicants should possess advanced degrees and must hold an affiliation with an academic center, not-for-profit institution, or for-profit entities such as biotechnology start-up companies.
- Letters of support from the principal investigator’s (PI) institution are required and should describe the nature of the PI’s appointment and commitments to the PI, such as lab and office space, technical assistance or travel funds.
An expert review board of judges will consider all proposals received by the deadline. The review board, appointed by the IADR Board in consultation with GSK, will include international experts acknowledged as leaders in their fields. No members of the IADR Board of Directors may serve as members of the review board.
Criteria for review will include:
1) Originality and novelty of the oral care, (as defined above), research proposal. Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Are existing paradigms challenged or new methods or technologies developed?
2) Potential importance to oral health and quality of life. Does the study address an important problem? What effect might this project have on current methods and concepts that drive this field?
3) Evidence of the applicants’ abilities to conduct the proposed research. Are the named investigators appropriately trained to carry out this work? Is the work proposed appropriately matched to the experience levels of the researchers?
4) Appropriateness of methodologies and scope. Does the scientific environment in which the work will be done contribute to the probability of success? Does the project employ useful collaborative arrangements? Is there evidence of institutional support?
5) Budgetary emphasis should be on additional technical assistance, equipment, etc. related specifically to pursuing the new idea or method rather than providing significant salary support for principal investigators.
The IADR and Review Panel members will treat all application materials submitted for consideration for funding in a confidential manner. The IADR and Review Panel members will not use application materials submitted by prospective awardees and evaluation materials for any purposes other than those related to the acceptance and evaluation of applications or the administration of awards. GSK is not privy to the review and judging process.
GSK shall not use, disclose, or transfer for any purpose other than the award program any information or intellectual property disclosed in the course or as part of the Award Program.
Proposals are limited to:
- Research Plan, (6-page limit),
- Biographical Sketch, (4-page limit); and
- Budget (tables for the Budget are included in the online submission package and are not part of the 6-page limit).
- Tables and figures are included in the 6-page limit.
- No appendices (other than investigator resumes and letters of support) are allowed.
- A title for the project and an abstract of no more than 350 words should also be provided by the applicant.
- Only online applications will be accepted.
- Space limitations will be defined by the online application program.
Research Plan (not to exceed 6 pages):
The research plan should be divided into:
Consultant/Collaborative/Contractual Arrangements - If needed, include letters verifying any consulting, collaborative, or contractual arrangements necessary for the conduct of the research.
Biographical Sketch (not to exceed 4 pages)(One for each investigator):
- The sketch should include the applicant's name and position title.
- This should be followed by education/training information (earliest training and degree first), and
- Research and professional experiences (concluding with the current position).
- Complete references to all scientific/clinical publications during the past four years, as well as pertinent earlier publications should be included.
- All biographical sketches should include the following: Education Degrees, Postgraduate Training, Postgraduate Qualifications, Awards, Current Position Positions Held, Voluntary Experience, Committee Assignments, Professional Memberships, Activities/Interests, Bibliography. A biographical sketch for each applicant should be submitted.
Budget and Budget Justification:
A completed budget is required for acceptance. Please supply explanation and justification where necessary. Per IADR policy, reimbursed institutional overhead cannot exceed eight (8) percent of the award amount. You MUST download and utilize one of the pre-defined GSK's project budgets and save it on your computer. For projects lasting 12 months or less, please complete the "One Year Budget Form". For projects lasting between 12 and 24 months, please complete the "Two Year Budget Form", which breaks down the budget by year. Projects longer than 2 years will not be considered.
Time Frame for Submission, Review, and Award:
December 12, 2014
Award(s) Announcement and notification:
Award Policies and Conditions:
IADR shall be responsible for establishing and enforcing all rules and regulations concerning the grant of Award(s) and complying with all applicable laws, rules and regulations.
Successful applicants will be required to sign a Letter of Agreement and Acceptance concerning the conditions and policies under which the grant is awarded prior to receipt of the Award(s).
Innovation in Oral Care grants are not renewable. Any continuation of funding after the initial grant is contingent upon GSK interest in a specific project and subsequent negotiation with the applicants beyond the Innovation in Oral Care grant per se.
Financial Administration and Reports:
The Award(s) will be made to the grantee institution and not to the individual. The clinical investigator(s) is responsible for the scientific conduct of the research and the institution is responsible for financial and administrative matters. The institution is responsible for administration of the funds in accordance with acceptable policies and procedures for sponsored project accounting and in accordance with the terms and conditions of the Award(s).
Projects must be completed within two years. For those projects that require more than one year for completion, the principal investigator must provide an interim report. Payment will be made in two installments. The second payment is contingent upon receipt of the interim report where appropriate.
IADR and GSK reserve the right to make no Award.
Human Subjects, Radiation Safety and Environmental Health Issues:
All research conducted as part of the GSK - IADR Innovation in Oral Care Awards involving human subjects shall follow all applicable laws, regulations, and guidelines and, if involving human subjects or otherwise appropriate, have the approval of the relevant Institutional Review Board (IRB). Copies of the IRB approval must be submitted prior to funding of the Award(s).
All presentations and publications (as well as posters and/or abstracts at scientific meetings) that result from the support provided by the Award(s) ward should acknowledge that support in writing. The following citation is suggested: "Funding for this project [research title], has been provided through an Innovation in Oral Care Award, conducted by the International Association for Dental Research and sponsored by GlaxoSmithKline Consumer Healthcare."
Except for disclosures to IADR or GSK as agreed to by applicant, all applicants shall agree not to disclose their application or the contents thereof to others until June 30, 2015. After the judging process has been completed, GSK will have access to applicant names, their institutions, the proposal title and abstract only, and may wish to discuss potential commercialization of the concepts disclosed in the applications with the applicants, if the applicants so agree.
Completed applications should be submitted online at the link above before the closing date of December 12, 2014!.
Further information can be obtained from the Sheri S. Herren, Strategic Programs Manager (Email: firstname.lastname@example.org).
Interested parties are welcome to submit a brief proposal letter outlining the research to IADR and asking for a determination as to whether such research would qualify for consideration.
Jake Jinkun Chen, Tufts University
and co-authors Qisheng Tu and Lily Dong
A New Therapy for Treating Diabetic Periodontitis
Yvonne Kapila, University of Michigan
and co-authors J Fenno, and Alexander Rickard
The Effect of Nisin on Dental Plaque Biofilm Communities
Keith L. Kirkwood, Medical University of South Carolina, Charleston, USA
and co-author Frank Alexis of Clemson University
Novel Anti-Inflammatory Nanoparticle Scaffolds for Periodontal Treatment
"Novel Peptide Mimetics to Reinforce Dentogingival Attachment"
Bernhard Ganss, University of Toronto, ON, Canada and co-author Eli Sone
"Controlled Release in situ of Antibiofilm Agents via PH-activitated Nanoparticle-Carriers"
Marlise Klein, University of Rochester, New York, USA and co-authors, Danielle Benoit, Hyun Koo and Megan Falsetta Wood
"Dentotropic Pluronics as Novel Formulation Excipients for Oral Hygiene Products"
Dong Wang, University of Nebraska Medical Center, Omaha, USA and co-author Richard Reinhardt
“The Influence of Low-Temperature Plasma on Biofilms”
Simone Duarte, New York University, USA and co-investigators Deepak Saxena and Nelson Silva
“Peptide Mimetics of LL-37 as Novel Therapeutics for Periodontitis”
Christopher Irwin, Queen’s University, Belfast, Ireland and co-investigators Fionnuala Lundy and Brian Walker
“Novel Sustained Release Varnish of Anti-Biofilm/Anti-Quorum-Sensing Agents Against Oral Biofilms”
Doron Steinberg, Hebrew University, Jerusalem, Israel and co-investigator Michael Friedman
“A Natural Formulation for Patients Diagnosed with Xerostomia”
Scott DeRossi - Medical College of Georgia, Augusta, USA and co-investigators Douglas Dickinson, Stephen Hsu, Stephen Looney and Kalu Ogbureke
"SCPSS: Enabling Technologies for Salivary Biomarkers for Clinical Applications"
David T. Wong - University of California, Los Angeles, USA
"Development of Small Molecules that Inhibit and Disperse Carciogenic Biofilms"
Hui Wu - University of Alabama at Birmingham, USA and co-investigators Suzanne Michalek and Christian Melander (North Carolina State University)
“Multifunction Nano-biomaterials for Implant-based Dental Reconstruction Products”
Robert Patrick Allaker, Queen Mary & Westfield College, University of London, UK and co-investigators Jie Huang, Department of Mechanical Engineering, University College London and Guogang Ren, School of Aerospace, Automotive and Design Engineering, University of Hertfordshire Hatfield, UK
“Therapeutic Potential of Citrus Auraptene for Periodontal Disease”
Daniel Grenier, Groupe de Recherche en Ecologie Buccale, Université Laval, Quebec, Canada and co-investigator Francesco Epifano, Faculty of Pharmacy, University G. D'Annunzio of Chieti-Pescara Chieti Scalo, Italy
“POC Immunoassay Test Strip for the Diagnosis of Periodontal Disease”
Craig Miller, University of Kentucky College of Dentistry, Lexington, USA and co-investigator Jeffrey L. Ebersole
“Nanostructured Peptide Hydrogels and Stem Cells for Dentin-Pulp Complex Regeneration”
Rena D'Souza, Baylor College of Dentistry, Texas A&M Health Science Center, USA and co-investigators Jeffrey Hartgerink, Departments of Chemistry and Bioengineering, Rice University, Houston, Texas and Gottfried Schmalz, University of Regensburg, Germany
“Development of Oxantel to Prevent Periodontopathogenic Biofilm Formation”
Eric Reynolds, Melbourne Dental School, The University of Melbourne, Australia and co-investigator Stuart Dashper
“Optical Coherence Tomography for Non-Invasive Diagnosis of Periodontal Disorders"
Sandra Bordin, University of Washington, Seattle, USA and co-investigator Xingde Li
“A Natural Edible Agent for Reduction of Oral Biofilm”
Urban Hägg, Lakshman Samaranayake, Richard Kao, and Michelle Yuen, The University of Hong Kong, Hong Kong
"Targeting Post-transcriptional Signaling for Periodontitis"
Keith Kirkwood, Medical University of South Carolina, USA
“SPITDX: A Universal Platform for Salivary Biomarker Detection"
David T.W. Wong, Wei Lao, and Fang Wei, University of California, Los Angeles, USA
“Noninvasive Gingival Delivery of FC-Conjugated Fusion Compounds”
Toshihisa Kawai, Forsyth Institute, Boston, Massachusetts, USA
"Characterization of a Novel Calcitonin Gene-Related Peptide (CGRP) Cleavage Enzyme"
Fionnuala T. Lundy and David Orr, School of Medicine and Dentistry, Queen’s University, Belfast, Ireland and University of Ulster at Coleraine, Coleraine, United Kingdom
“Improving Oral Care Using Tea Tree Oil and Its Derivatives"
Gordon Ramage, Glasgow University Dental School & Hospital, Glasgow, Scotland
"A Novel Therapeutic Approach to Prevent Formation of Cariogenic Biofilm"
Hyun (Michel) Koo, Thomas Foster, and Robert Quivey, Eastman Department of Dentistry, University of Rochester, USA
"A Novel Therapeutic Human SCFV-Diabody For Aggressive Periodontitis"
Yen-Tung Andy Teng, Eastman Department of Dentistry, University of Rochester, USA
"Targeting IKK/NF-KB For Periodontitis"
Cun-Yu Wang and Lijian Jin, University of Michigan, School of Dentistry, USA, University of Hong Kong, Hong Kong
"A Novel Antibacterial Approach to Reduce Caries in Children"
John Featherstone, Ling Zhan, Pamela DenBesten, Charles Hoover, and Stuart Gansky, University of California – San Francisco, USA
"A Novel Treatment for Cold Sores"
Peter Holbrook, Thordis Kristmundsdottir, Halldor Thormar, and Skuli Skulason, University of Iceland, Iceland
"A Novel Formula Protects Infants from HIV"
Lin Tao, University of Illinois at Chicago, USA
"Novel Dental Desensitizing Agent Based on a Biomimetic Approach"
Jack Ferracane, John Mitchell, and Jack McCarthy, Oregon Health & Science University, Portland, USA
"Development of Pharmaceutical Technology for Sustained Release Delivery Systems of Antibacterial Peptides: The Effect on Dentla Biofilms and Oral Diseases"
Doron Steinberg, Amram Mor, Michael Friedman, and Gilad Bachrach, Hebrew University Hadassah School of Medicine, Jerusalem, Israel
"Prevention of Candida Associated Denture Stomatitis"
Spencer W. Redding, Jose Lopez-Ribot, H. Ralph Rawls, and Gregg Siegel, University of Texas-San Antonio, USA
"Binding of Quorum Sensing Molecules as Antibiofilm Strategy"
Marie-Claude Amoureux, Peter Grandics, Nandani Rajapakse, and Susan Szathmary, Clarigen Inc., Carlsbad, CA, USA